purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation srpt earnings call period ending december image source motley fool sarepta therapeutic srpt q earnings callfeb pm etcontents prepared remark question answer call participant prepared remark operatorgood afternoon welcome sarepta therapeutic fourth quarter full year earnings call time participant listenonly mode speaker presentation questionandanswer session operator instruction reminder today program recorded time turn call francesca nolan executive director investor relation corporate communication please go aheadfrancesca nolan executive director investor relation corporate communication thank shannon thank joining today call earlier afternoon released financial result fourth quarter full year press release available website sareptacom q filed security exchange commission afternoon joining u call today doug ingram ian estepan dallan murray dr louise rodinoklapac formal remark open call qa would like note call making number forwardlooking statementsplease take moment review slide webcast contains forwardlooking statement forwardlooking statement involve risk uncertainty many beyond sareptas control actual result could materially differ forwardlooking statement risk materially adversely affect business result operation trading price sareptas common stock detailed description applicable risk uncertainty encourage review company recent annual quarterly report form k filed sec well company sec filing company undertake obligation publicly update forwardlooking statement including financial projection provided today based subsequent event circumstance turn call president ceo doug ingram provide overview recent progress doug doug ingram president chief executive officer thank fran way everyone frans birthday yesterday happy birthday fran good afternoon everyone thank joining sarepta therapeutic fourth quarter financial result conference call led exceptional launch elevidys continuing performance approved pmos exondys vyondys amondys announced afternoon another strong quarter full year growth quarterly growth serve patient community preannounced january jpmorgan conference fourth quarter total net product revenue came million growing quarter prior year full year net product revenue achieved billion growing prior year addition continuing strong performance among three approved therapy elevidys performance particularly impressive reflects firstinclass launch excellence notwithstanding label limited four fiveyearolds representing total duchenne population elevidys net product revenue million quarter million full year exceptionally proud team performance speaks level preparation attention detail expert understanding aspect launching innovative rare disease therapy course passion bringing better life living duchenne dallan murray chief customer officer speak remark shortly also continue exercise discipline fully integrated commercialstage biotech organization profitable gaap basis fourth quarter achieved nongaap profitability third quarter exited approximately billion cash cash equivalent restricted cash investment balance sheet cfo ian estepan provide color financial performance shortly also advanced pipeline fourth quarter fourth quarter submitted bla supplement elevidys goal expanding label removing age ambulation restriction transitioning approval accelerated traditional february year fda accepted supplement review set june target review completion date fourth quarter also commenced emergene trial srp treat lgmd type e also january year announced positive result trial momentum part b investigating use nextgeneration peptide conjugated pmo srp treat duchenne patient exon amenable dr louise rodinoklapac head research development provide color pipeline progress shortly starting one approved therapy million sale modest pipeline short cash runway little ambition grit set build sustainable mature biotech organization improve life greatest possible number duchenne patient along way become leader use rna gene therapy treat rare genetic disease successful plan year achieved vision expand ambition rely scientific financial strength intend advance internal pipeline also bring external innovation grow incrementally great multiple short going important year turn call chief customer officer dallan murray dallandallan murray senior vice president chief commercial officer thank doug good afternoon fourth quarter represented strong finish already impressive year team generated billion net product revenue milestone sarepta previously noted net product revenue totaled billion consisting roughly million pmo franchise million launch elevidys first gene therapy approved patient duchenne muscular dystrophy accomplishment stand merit performance surpassed internal projection external consensus seventh year pmo franchise grew net product revenue double digit nearly million net product revenue previous year delivered growth organically without taking price increase approved pmo product growth represents increase number patient serving reflecting commitment duchenne community turning elevidys extremely pleased launch execution exceeding lofty expectation fact million net product revenue surpassed combined revenue five gene therapy launch past month remarkable given elevidys approval occurred past summer success elevidys show gene therapy commercially viable providing hope patient duchenne genetic condition unmet need revenue quantify success launch externally measure support patient preparation deliberate intense process put test narrow label team responded challenge incredible commitment supporting eligible four fiveyearold patient fourth duchenne launch knowledge experience played significant role team rallied worked together rapidly supported patient approaching sixth birthday risk becoming ineligible therapy ensuring eligible patient left behind motivates u let u review result fourth quarter starting elevidys net product revenue quarter roughly million represented nearly increase q pleased penetration small narrow segment duchenne population fourtofiveyearold label presented number unique executional challenge relevant moving forward firstly significant proportion patient age group yet diagnosed given average age diagnosis around five united state secondly diagnosed lot time fully educated duchenne mean patient family need understand diagnosis become aware therapy option go involved longer pretreatment process pmos one example antibody testing top patient must also secure access elevidys short time window team found race time help patient finally relatively small number diagnosed fourtofiveyearold patient result situation working prevalent population quickly within first half year flip side many dynamic reversed patient transitioned decline phase disease illustrated realworld experience pmos see larger proportion treated older age group top larger diagnosed patient pool expect see significant additional growth within existing population first half year notably however time label expansion expect cleared way older patient get dosed rapidly possible upon eligibility would caution analyst therefore use current younger population frame reference market potential overall population team preparing speak broad label focus building upon successful launch execution date access capacity place execute successfully broader label scenario let u take look pmo franchise whole previously mentioned net product revenue million exceeded full year guidance million performance represents solid revenue growth across three brand fact vyondys amondys continued doubledigit growth trajectory looking fourth quarter team delivered roughly million net product revenue flat versus q net product revenue roughly million may recall q earnings call cautioned around keeping guidance million year due increase quartertoquarter lumpiness observing time looking retrospect clear pmo performed exactly expected guided finally performance discussed pmo business achieved despite incredible effort elevidys launch notably saw minimal impact pmo business elevidys cannibalization given narrow age range closing sarepta set new standard gene therapy launch elevidys beat external expectation delivered roughly million equally important continue increase number patient support pmos globally continue immensely proud missiondriven team combining pmo gene therapy business exceeded billion net product revenue first time entered momentum let turn call head rd chief scientific officer dr louise rodinoklapac louiselouise rodinoklapac executive vice president chief scientific officer thanks doug year great accomplishment sarepta advancement science health wellbeing patient living rare disease also remembered defining moment genetic medicine june fda granted accelerated approval elevidys first gene therapy treat duchenne muscular dystrophy since time successfully treating ambulatory pediatric patient aged four five year duchenne confirmed mutation dmd gene two week ago doug mentioned thrilled announce fda accepted filed efficacy supplement elevidys whereby evaluate broadening approved indication elevidys removing age ambulation restriction converting elevidys accelerated approval traditional approval receive accelerated approval elevidys nonambulant population united state envision study also called srp serve confirmatory study population envision global randomized doubleblind placebocontrolled twopart study evaluating safety efficacy delandistrogene moxeparvovecrokl gene therapy nonambulatory older ambulatory individual duchenne study ongoing remaining patient enrolled outside united state u enrollment completed remaining recruitment occurring exus confident ability complete trial moving limbgirdle muscular dystrophy lgmd program january th announced screening underway study srp also known emergene study pleased share first patient successfully dosed study remind emergene phase multinational openlabel clinical trial srp treatment limbgirdle muscular dystrophy type e betasarcoglycanopathy primary endpoint emergene expression betasarcoglycan extremely important endpoint program sarcoglycanopathies including lgmdd lgmdc field gene therapy explain betasarcoglycanopathy characterized mutation betasarcoglycan gene sits complex membrane called sarcoglycan complex important function preventing muscle damage contraction sarcoglycan complex subcomplex dystrophinassociated protein complex dapc defective sarcoglycan protein result loss reduced expression sarcoglycan well protein complex dystrophin therefore restoring missing protein betasarcoglycan able restore functional complex membrane thereby restore function muscle earlier month opportunity participate speak foundation lgmd scientific workshop also featured official fda including drs mark verdun well patient caregiver clinician among others key takeaway workshop included perspective traditional trial design suitable certain type lgmd ensure therapy best chance success totality evidence must considered drs mark verdun also expressed strong support regulatory flexibility higher tolerance uncertainty rare disease lgmd replacing native protein well support surrogate endpoint gene therapy currently treatment exist effectively treat lgmde lgmds emergene study enroll participant ambulatory nonambulatory age four older hold great promise individual suffering lgmde lay foundation lgmd program well provide viable regulatory pathway support development future gene therapy rare ultrarare disease data combined positive expression functional data shared initial lgmde study srp also published nature medicine earlier year voyagene study srp establishes safety experience across broader patient population together totality evidence reminder voyagene phase study evaluating srp treatment lgmde patient age older ambulant population age nonambulant population primary endpoint safety change betasarcoglycan expression expect clinical result year moving rna platform also pleased recently announce positive result part b momentum study study srp based data generated date believe srp represents bestinclass therapy efficacy perspective momentum global multiascending dose clinical trial srp nextgeneration peptide phosphorodiamidate morpholino oligomer treatment patient duchenne amenable exon skipping previously discussed based result believe path forward nda planning meeting fda discus accelerated approval anticipate meeting occur third quarter regarding postmarketing study pmos mentioned completed enrollment essence trial postmarketing requirement golodirsen casimersen reminder essence twoyear study due readout early addition pleased completed enrollment mison study doseranging postmarketing commitment exondys mison randomized doubleblind safety efficacy dosefinding study comparing approved dosage eteplirsen mg per kg weekly dosage provides significantly higher exposure mg per kg weekly mison twopart phase study fully enrolled october patient remain committed rapidly diligently advancing mison sharing data soon becomes available conclusion month ahead filled great promise advance mission serve patient around world living rare disease turn call ian estepan update financial result ianian estepan chief financial officer thanks lrk good afternoon everyone afternoon financial result press release provided detail fourth quarter nongaap basis well gaap basis please refer press release available sareptas website full reconciliation gaap nongaap financial result get result wanted flag beginning fourth quarter amortization inlicensed right income tax expense benefit longer excluded nongaap result company added income tax effective adjustment represent estimated income tax impact pretax nongaap adjustment based applicable effective income tax rate nongaap financial result fourth quarter full year updated reflect change comparability purpose three month ended december st company recorded total revenue million consists net product revenue collaboration revenue compared revenue million period increase million net product revenue fourth quarter elevidys million net product revenue fourth quarter pmo exon skipping franchise million compared million period fourth quarter individual net product sale million exondys million amondys million vyondys increase net product revenue primarily reflecting increasing demand pmo product well net product revenue associated sale elevidys quarter ended december st recognized million collaboration revenue compared million period revenue primarily relates collaboration arrangement roche quarter ended december st company recognized million contract manufacturing collaboration revenue associated multiple batch commercial elevidys supply delivered roche similar activity ended december st reimbursable codevelopment cost roche agreement totaled million fourth quarter compared million period gaap basis reported net income million per basic per diluted share net loss million per basic diluted share fourth quarter respectively reported nongaap net income million per diluted share fourth quarter compared nongaap net loss million per diluted share fourth quarter fourth quarter recorded approximately million cost sale compared million period increase cost sale primarily reflect increasing demand pmo product increase royalty payment due elevidys sale similar activity writeoff certain batch product meeting quality specification three month ended december st similar activity period gaap basis recorded million million rd expense fourth quarter respectively yearoveryear decrease million decrease primarily due decrease manufacturing expense upfront milestone expense nongaap basis rd expense million fourth quarter compared million period decrease million turning sga gaap basis recorded approximately million million expense fourth quarter respectively increase million increase driven primarily increase professional service compensation personnel expense partially offset decrease stockbased compensation nongaap basis sga expense million fourth quarter compared million period increase million gaap basis recorded million income net fourth quarter compared million period change primarily due increase accretion investment discount net due increase interest rate approximately billion cash cash equivalent investment longterm restricted cash december st conclude incredibly pleased achieve first quarter profitability gaap perspective impressive reach milestone second quarter elevidys launch highlight leverage business reason dallan outlined maybe lumpiness bottom line first half said expansion label expect highly profitable full year also previously noted preparation serve community event label expansion continuing ramp manufacturing elevidys continued investment apparent first quarter financials remainder year thrilled resource hand continue build inventory needed deliver elevidys duchenne community turn call back doug start qa dougdoug ingram president chief executive officer thank much ian shannon let u open call question question answer operatorthank operator instruction ask please limit one question first question come line gena wang barclays line opengena wang barclays analyst thank think operator voice cut know many question ask ask two quick question one elevidys proposed label based fda feedback purely sareptas end second regarding emerging phase study limbgirdle e confirmed fda patient would sufficient protein level approvabledoug ingram president chief executive officer yeah thank much question gena future one question per analyst appreciate question let answer basis request expand label removing age ambulation restriction driven science want clear midst review pleased progress review far early right give substantive view division perspective view science totality evidence support label extension asked right answer perspective right answer science right answer policy perspective right answer patient living duchenne muscular dystrophy hope north star regard respect emergene say protocol shared reviewed fda basis discussion including end study given u blessing commence study provide additional information level expression likely predict clinical benefit later date would note prior study two cohort seen robust expression betasarcoglycan protein absence sole exclusive degeneration patient lgmd type e thank youoperatorthank next question come line tazeen ahmad bank america line opentazeen ahmad bank america merrill lynch analyst hi good evening thanks taking question wanted get sense look expansion label model cog especially patient get therapy time wait patient presumably go higher get older patient reasonable range cog assuming thank youdoug ingram president chief executive officer yeah ian turn youian estepan chief financial officer sure cost perspective pretty clear targeting obviously financials reported today see much higher time heavier patient get therapy obviously preexpense inventory exhausted see cog obviously start increase margin start decline range guiding obviously give complete clarity around suspension could coming online much higheryielding process time older heavier patient coming would offset weight said time would see erosion margin currently modeling around probably reasonableoperatorthank next question come line joseph schwartz leerink partner line openunknown speaker leerink partner analyst hi thanks taking question joe congrats great question one question u manufacturing recent acquisition catalent novo expected expiration agreement catalent end year guy thinking manufacturing moving forward term capacity potential expanded label year potential supply constraint near term thank youdoug ingram president chief executive officer yeah sound like question first think might misunderstanding sort let clear agreement catalent end end year longterm relationship catalent good partner perspective impact acquisition catalent novo holding understand novo holding would acquiring entity whole glprelated manufacturing think going sold novo nordisk novo holding hold rest catalent run way run today direction discussion senior management catalent quite confident business usual good generally supply perspective say done together last since well beginning journey manufacturing cmc perspective yeah would nothing miraculous fact science hard workdriven sit today done really brilliant job serving community continuing brilliant job serving community course year partner catalent feeling good areoperatorthank next question come line gil blum needham company line opengil blum needham company analyst hi everyone good afternoon thanks taking question know may knowable remind u population divide ambulatory nonambulatory patient kind median age loss ambulation thanksdoug ingram president chief executive officer give broad stroke epidemiologically ambulatory nonambulatory patient dallan recent estimate loss ambulationdallan murray senior vice president chief commercial officer cut second say diagnosed patientsdoug ingram president chief executive officer said average age loss ambulationdallan murray senior vice president chief commercial officer oh average age loss ambulation think louise would probably better data would depending different publication range louise sound rightlouise rodinoklapac executive vice president chief scientific officer yeah slightly earlier point difference yeahgil blum needham company analyst thank youoperatorthank next question come line brian abraham rbc capital market line openunknown speaker leerink partner analyst hi leonard brian maybe ask question ok quite two clarify application process respect elevidys guess conversion full approval label expansion two separate question fda potentially separate timeline review discussion around separated guess related mentioned prepared remark thinking broadlabel scenario mentioned get accelerated approval nonambulatory setting guess part scenario something heard fda preparing possibility thanksdoug ingram president chief executive officer couple thing yes essentially two issue agency time one modifying label expand label provide access much broader population patient said bear repeating bla supplement requested removal age ambulationrelated restriction label believe founded science course second question view satisfied requirement confirmatory trial entire approval translated accelerated traditional approval many different scenario obviously going dialogue breadth label course dialogue portion confirmed traditional approval portion confirmed remain accelerated approval many iteration strong view think science justifies first administrative perspective timeline identical june target completion date issue address issue june pleased june know guiding people end august perspective substantive issue going happen review going subject review early day would say pleased least engagement division thus far work discussion want overpromise end also say lot different iteration perspective priority number one broadest possible label two issue discussing first foremost focused broadest possible label giving potential access hopefully better life greatest number patient course important u secondary issue translating accelerated traditional breadth separate discussion work discussion work agency june return date thatoperatorthank next question come line kostas biliouris bmo capital market line openkostas biliouris bmo capital market analyst thanks taking question congrats impressive progress one quick question u assume label restrict elevidys use ambulatory patient age straightforward would physician importantly payer clearly determine whether someone ambulatory given patient losing ambulation progressively may stage ambulation status unclear would clear physician payer determine someone eligible thank youdoug ingram president chief executive officer yeah ok thank much question first let clear resist assumption may get ambulatory alone course point seeking removal ambulatory restriction point ambulation label today question physician determine ambulation mean short answer left medical judgment physician good guidance medical practice based functional assessment functional test welldefined approach probably common perhaps gold standard approach definition synergy patientreported continuous use wheelchair without ambulation verified physician inability patient walk meter unassisted would typical functional assessment physician would use determine ambulatory status enormously difficult functional assessment conclusion make physiciansoperatorthank next question come line neena bitrittogarg deutsche bank line openneena bitrittogarg deutsche bank analyst hey guy thanks taking question follow last question could remind u data included filing patient nonambulatory kind clarify thanksdoug ingram president chief executive officer yeah data child year old separate study call study went obviously also ongoing study envision study nonambulatory patient ongoing placebocontrolled trial safety study obviously made available fda continuous basis support dla supplementsoperatorthank next question come line tim lugo william blair line opentim lugo william blair analyst thanks question discus level warehousing currently occurring dmd community maybe subpopulation ahead potential expansion summer aware know focus ambulatory agerelated anything else though also looking life function cell populationsdoug ingram president chief executive officer well sure mean warehousing honest going exceptional amount demand therapy label expanded physician community family duchenne muscular dystrophy stand prepared build material lot available fully serve demand course dallan thought warehousing question itselfdallan murray senior vice president chief commercial officer yeah think related pmos warehousing pmos anticipation gene therapy worried leading initial launch team exceptional job making sure happen see widespread warehousing patient getting delayed really warehousing people foregoing pmo anticipation gene therapy think mentioned script one thing particularly pleased year continued incredibly excellent execution pmo team patient eligible gene therapy elevidysoperatorthank next question come line uy ear mizuho line openuy ear mizuho security analyst hey guy thanks taking question going back exon skipping product asking guidance anything help u understand first half year prior quarter yearoveryear growth relatively strong first half wondering think first half three product thanksdoug ingram president chief executive officer provided guidance pmos year well saw good performance three pmos last year fact amondys vyondys still growing double digit one thing interesting seeing right probably see significant amount cannibalization elevidys course significant impact pmo feel good three rnabased therapy operatorthank next question come line salveen richter goldman sachs line openunknown speaker leerink partner analyst hi lizzie salveen thank much taking question label elevidys expanded broader population open think physician might prioritize patient treat first context constraint thank muchdoug ingram president chief executive officer yeah issue physician going grapple number constraint one thing asked remember need ensure always prioritizing great outcome safety instance shortterm revenue need make sure physician physician know going certainly consider need make sure infuse station follow appropriately likely require prioritize station consider therapy short answer invade process medicine decide compelling argument across spectrum one hand may well physician want prioritize young child get intervene damage done hand nonambulatory patient later patient race time station getting patient stopping damage late extraordinarily important going difficult decision physician going work sure whitepapers discussion among thought leader topic issue today slightly different one prioritization today given label ensure get kid label really come physician u get kid label age frailty available look bias bias tends type age range four five later age really trying get kid adoc get administrative process age six year old good news expand label issue go side deal issue prioritization like ultimately physician decision issue practicing medicine physiciansoperatorthank next question come line ritu baral td cowen line openritu baral td cowen analyst hi guy thanks taking question want follow shorter guidance given comment expect additional quote elevidys first half year least pdufa comment reflection fact reached sort runway four fiveyearold comment sort capacity system throughput getting many patient possible comment sort throughput capacity center point hopefully label expands thanksdoug ingram president chief executive officer yeah really capacity issue right think dallan commented opening remark label today population really fairly unique population first call know narrow age range four five year old alone really describe unique nature population beyond significant percentage patient yet diagnosed make unusual diagnosed remember getting diagnosed four year one day kid getting diagnosed five mean mean family faced likely devastating piece news far life come grove news understanding well enough go administrative process exists get approval get antibody test get infusion date get infused really unique population light give shoutout team particularly impressive one considers million product revenue year dallan really talking talking simply work prevalent population really unique population much narrowed might imagine four five middle year assuming label expansion would get place begin treating incident population opposed abolished prevalent population group good news june date request label expansion hopefully july broader label able serve much greater percentage populationoperatorthank next question come line david hoang citigroup line opendavid hoang citi analyst hi thanks taking question wanted ask little bit suspension manufacturing work active something like come online operationalized might improve marginsdoug ingram president chief executive officer excited suspension perspective still ton work couple thing think advanced actually suspension work srp actually getting great result suspension perspective limbgirdle program couple sarcoglycan program actually transitioned suspension making great progress focus specifically elevidys engineering realm right suspension done liter another liter start next month liter far getting really tremendous enhancement yield really good product quality go well goal suspension process available commercially moonshot goal part keeping patient front center going try move fast possible hopefully history prove cope audacious plan serve really excited far might capacity perspective go around world partner roche cog perspective going require work clarification get run done modest multiple seeing multiple time greater yield suspension get icellis process ian mentioned still drive right margin probably hear voice certain amount enthusiasm manufacturing approach suspension approach still early day engineering realm trying excited could mean ability bring therapy across world lower cost good go across worldoperatorthank next question come line mike ulz morgan stanley line openmike ulz morgan stanley analyst hey guy thanks taking question maybe quick one timing since pdufa date granted two month ahead expectation curious thinking probably get decision close pdufa date fda still really committed rapidly reviewing might get answer sooner thanksdoug ingram president chief executive officer reason believe fda committed rapidly reviewing said still lot work done think would prudent u assume target completion date june date going get answer planning june even though going think anyone think try move fast possible assuming june going get label expansion request answeredoperatorthank next question come line danielle brill raymond james line openunknown speaker leerink partner analyst hey guy alex danielle thanks taking question maybe pmo confirmatory trial fully enrolled could remind u whether expect data mison yeardoug ingram president chief executive officer read operatorthank next question come line brian skorney baird line open brian skorney baird line openunknown speaker leerink partner analyst hi charlie brian thanks taking question wondering heard anything roche regarding timeline ema well european opportunity come online would supply limitation resulting know comfortable expansion label bringing whole another content think would prioritization region thank youdoug ingram president chief executive officer well roche publicly saying goal submit relates supply supply plan include partner rocheoperatorthank youdallan murray senior vice president chief commercial officer one quick followup previous question around mison timing one thing remind everyone dose compare dos drug data read comparative mg per kg compared either mg mg per kg risk drug pulled marketoperatorthank next question come line kristen kluska cantor fitzgerald line openrich mille cantor fitzgerald analyst hi rich miller kristen thanks taking question since launching able talk profile dmd patient looking get elevidys changed put another way imagine highly engaged caregiver ready elevidys day one seeing patient coming forward month commercial experience caregiver get child line elevidys thanksdoug ingram president chief executive officer yeah would say broadest stroke going substantial demand therapy think changed think anticipated launch think changed launch duchenne muscular dystrophy devastating disease opportunity offered elevidys important one think physician understand family duchenne muscle dystrophy understand well dallan additional color view please share themdallan murray senior vice president chief commercial officer think broadly speaking exactly right doug seeing real major change term patient coming set small population soon getting diagnosed discussion doc coming enrollment form working patient fast prior aging major difference example big kind bolus patient initially came different steady clip essentiallyoperatorthank next question come line anupam rama jp morgan line openanupam rama jp morgan analyst hey guy thanks much taking question conference january talked site active half site dosed patient give u sense kind first couple month year thanks muchdoug ingram president chief executive officer yeah mean believe remains accurate answer dallan give u update change thatdallan murray senior vice president chief commercial officer anupam really changed much obviously higher proportion site dosed actively looking daily basis flexible model bring new site get trained ready needed got enough site running got great geographic coverage team also ready support serve needed theredoug ingram president chief executive officer really want give kudos team think everybody know goal try get much site end would recordsmashing gene therapy launch going aspiration maybe someday could get site would trained running team got know site also way got something give enormous amount pride said earlier call prioritize revenue patient safety great outcome far important u ensure great outcome team done ton direction site activated welltrained good shape able safely infuse therapy get good outcome consistent outcome important laudable safety profile full body infusion gene therapy want ensure remains case long term short term course lot program around ability access expert every physician opportunity get right kind information inform way infuse monitor patient react something unique sure anyone else ever done kind work done great shape right serve community serve responsibly really proud team right frankly also explains revenue dallan murray senior vice president chief commercial officer thanks doug speaking team get u direct answer anupams question closing site dosed exactly said increasing goanupam rama jp morgan analyst right thank youoperatorthank would like turn call back doug ingram closing remarksdoug ingram president chief executive officer thank shannon thank joining u today thank insightful question appreciate risk repeating think extraordinarily important year sarepta lot folk team concert patient community investigator physician frankly moved heaven earth get u today think fastmaturing fully integrated biotech organization committed bringing better life patient duchenne muscular dystrophy limbgirdles serious rare disease actually going even significant successful going put u position lot good lot rare disease patient reward stuck u invested better life patient remind successful year broaden label elevidys meet goal year going leverage acumen financial strength talent team advancing internal pipeline looking external innovation goal growing even elevidys incrementally multiple going build big ambition successful said need focus successful team prepared look forward updating along way well thank lovely eveningoperatoroperator signoff duration minutescall participantsfrancesca nolan executive director investor relation corporate communicationsdoug ingram president chief executive officerdallan murray senior vice president chief commercial officerlouise rodinoklapac executive vice president chief scientific officerian estepan chief financial officergena wang barclays analysttazeen ahmad bank america merrill lynch analystunknown speaker leerink partner analystgil blum needham company analystkostas biliouris bmo capital market analystneena bitrittogarg deutsche bank analysttim lugo william blair analystuy ear mizuho security analystritu baral td cowen analystdavid hoang citi analystmike ulz morgan stanley analystrich mille cantor fitzgerald analystanupam rama jp morgan analyst srpt analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy